High Dose Local Photon Irradiation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance the Abscopal Response in a Murine Pancreatic Carcinoma Model
Authors:
- Junya YamamotoJYJunya Yamamoto
- Yutaka TakahashiYTYutaka Takahashi
- Kazumasa MinamiKMKazumasa Minami
- Keisuke TamariKTKeisuke Tamari
- Shohei KatsukiSKShohei Katsuki
- Wataru TakenakaWTWataru Takenaka
- Shotaro TatekawaSTShotaro Tatekawa
- Kazuhiko HayashiKHKazuhiko Hayashi
- Yuji SeoYSYuji Seo
- Fumiaki IsohashiFIFumiaki Isohashi
- Kazuhiko OgawaKOKazuhiko Ogawa
- Masahiko KoizumiMKMasahiko Koizumi
Open Access
Abstract
Pancreatic cancer is an extremely treatment-resistant neoplasm to chemotherapy and immunotherapy. The combination of photon beam irradiation and anti-CTLA-4 antibody (C4) for the anti-tumor effect enhancement at local and distant tumors (abscopal tumors) was investigated using the pancreatic ductal adenocarcinoma (PDAC) mouse model. Pan02 cells were bilaterally inoculated to both legs of C57BL/6 mice. High dose photon beams in a hypofractionation or a single fraction were delivered to the tumors on one leg. Monotherapy with C4 via i.p. was not effective for PDAC. The high dose irradiation to the local tumors produced significant shrinkage of irradiated tumors but did not induce the abscopal responses. In contrast, the combination therapy of high dose photon beam irradiation in both hypofractionation and a single fraction with C4 enhanced the anti-tumor effect for abscopal tumors with significantly prolonged overall survival. The flow cytometric analysis revealed that the combination therapy dramatically decreased the regulatory T cell (Treg) proportion while increasing the cytotoxic T lymphocytes in both local and abscopal tumors. These results suggest that high dose photon beam irradiation plays an important role in C4 therapy to enhance the abscopal response with immune microenvironment changes in PDAC, regardless of the fractionation in radiation therapy.Keywords
Funding Information
- Japan Society for the Promotion of Science (Kiban C: 19K08151, Kiban C: 16K07173, Kiban B 18H02767)
- Princess Takamatsu Cancer Research Fund (16-24805)
This publication has 43 references indexed in Scilit:
- Immunogenic Tumor Cell Death Induced by Chemoradiotherapy in Patients with Esophageal Squamous Cell CarcinomaCancer Research, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapyCancer and Metastasis Reviews, 2011
- Regulatory T cells in tumor immunityInternational Journal of Cancer, 2010
- The Linear-Quadratic Model Is an Appropriate Methodology for Determining Isoeffective Doses at Large Doses Per FractionSeminars in Radiation Oncology, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- The secretion of HMGB1 is required for the migration of maturing dendritic cellsJournal of Leukocyte Biology, 2006
- Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- The radiation abscopal anti-tumor effect is mediated through p53International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002